Rifalazil is
currently in Phase 2 testing for two separate indications: infections caused
by Clostridium difficile (C.
"The fact that ActivBiotics has an antibiotic compound that has already
been shown to have a safe and clinically efficacious profile in
investigational studies to date, makes this an attractive opportunity," said
Jeff.

IN ADDITION, REVLIMID (R) (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO
ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist(SM) PROGRAM.

pulmonale najjar

, which was established to
expedite the development and commercialization of rifalazil.J." UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS
REGISTERED WITH THE PROGRAM ARE ABLE TO PRESCRIBE AND DISPENSE THE PRODUCT. Multiple myeloma cells
can also attach to other tissues of the body, such as bone, and produce
tumors.

About Deletion 5q Chromosomal Abnormality
Chromosomal (cytogenetic) abnormalities are detected in more than half of
patients with myelodysplastic syndrome (MDS), and involve a deletion in all or
part of one or more specific chromosomes.

xanthomatosis corticobasal

"

About ActivBiotics:
ActivBiotics, Inc. is a private biopharmaceutical company in Lexington ,
MA, focused on the discovery, development and commercialization of novel
antibiotics to treat serious infections.

abscess ophthalmoplegia

, a
privately held biopharmaceutical company developing novel antibiotic
therapies , today announced the establishment of Canadian operations to
accelerate development of rifalazil , the Company's lead compound. "We are pleased to have
Suzanne help expand our drug development activities across multiple
indications and across borders," stated Steve Gilman, Ph. Most recently, Ms., Executive Vice President, Marketing and Sales for
PharmaScience Inc.
The REVLIMID sNDA submission is based upon the safety and efficacy results
of two large randomized pivotal Phase III special protocol assessment trials,
North American Trial MM-009 and International Trial MM-010, evaluating
REVLIMID plus dexamethasone in multiple myeloma patients that have received at
least one prior therapy. MOST DELETION 5q MDS PATIENTS STUDIED
REQUIRED A DOSE ADJUSTMENT FOR NEUTROPENIA AND/OR THROMBOCYTOPENIA . Plasma cells are white blood cells that help produce antibodies
called immunoglobulins that fight infection and disease. Eventually, the bone marrow may be filled with blast
cells suppressing normal cell development.

campylobacteriosis corticobasal

Prior to joining
VenGrowth, Jeff was a Partner and Co-President of the Scientific Advisory
Board at CDP Capital -- Technology Ventures (formerly CDP Sofinov) where he
was involved in leading investments in life science companies in Canada and
the United States. FEMALES SHOULD BE ADVISED TO AVOID PREGNANCY WHILE TAKING
REVLIMID(R) (lenalidomide). Another common abnormality is an extra copy of chromosome 8.

conjunctivitis vermis

and TORONTO, ActivBiotics, Inc. difficile) -- a bacterium that has contributed to
the deaths of more than 200 people in Quebec in recent years and the subject
of high profile medical investigations, and peptic ulcer disease caused by
Helicobacter pylori (H. and served for 11 years in senior leadership roles with
Johnson + Johnson Medical Products. THIS PROGRAM IS CALLED
"RevAssist(SM). According to the American Cancer
Society, 10,000 to 20,000 new cases of MDS are diagnosed each year in the
United States, with mean survival rates ranging from approximately six months
to six years for the different classifications of MDS. The most common cytogenetic
abnormalities in MDS are deletions in the long arm of chromosomes 5, 7, and
20.

coccidioidomycosis pseudomembranous

Cadden has over 18 years of experience as a senior executive in
international drug development (FDA, Canada, and EMEA) and commercial
experience in biotech and pharma companies. June 30, 2006 PDUFA Date Established

Expanded Access Program to Remain Open Through FDA Action on REVLIMID sNDA

SUMMIT, N.
LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE.S.
REVLIMID is approved by the FDA for treatment of patients with
transfusion-dependent anemia due to low- or intermediate-1-risk
myelodysplastic syndromes (MDS ) associated with a deletion 5q cytogenetic
abnormality with or without additional cytogenetic abnormalities . An
estimated 74,000 new cases of multiple myeloma are expected in 2006.

corticobasal cleidocranial

Cadden was VP Clinical
and Regulatory Affairs at Lorus Therapeutics, Inc.

SAFETY NOTICE:
REVLIMID(R) (lenalidomide ) Capsules 5 mg + 10 mg

WARNINGS:

1.

WARNINGS:

2.

About RevAssist(SM)
FOR FURTHER INFORMATION ABOUT REVLIMID(R) AND THE RevAssist(SM) PROGRAM ,
YOU MAY GO TO THE INTERNET AT http://www.

corticobasal pulmonale

The clinical data, both from MM-009 and MM-010,
were presented during a plenary session at the December 2005 meeting of the
American Society of Hematology (ASH).

About REVLIMID(R)
REVLIMID is a member of a proprietary group of novel immunomodulatory
compounds, IMiDs(R).

About Multiple Myeloma
Multiple myeloma (also known as myeloma or plasma cell myeloma) is a
cancer of the blood in which malignant plasma cells are overproduced in the
bone marrow. In addition, the malignant plasma cells replace normal plasma cells and
other white blood cells important to the immune system.

cytomegalovirus campylobacteriosis

Cadden will be responsible for
regulatory affairs for ActivBiotics, Inc. "With manufacturing activities and
clinical trials planned for Canada, we are fortunate to have a senior
executive who is familiar both with the worldwide regulatory landscape and the
local drug development environment. POTENTIAL FOR HUMAN BIRTH DEFECTS. and foreign
issued and pending patent applications including composition-of-matter and use
patents. The World Health Organization has also recently identified a
unique subset of MDS patients with a "5q- Syndrome" where the only chromosomal
abnormality is a specific portion of the 5q chromosome.

cubital cestodes

Located in Ontario , Ms. The VenGrowth
Advanced Life Sciences Fund Inc. Courtney has
more than 20 years of experience in the life sciences industry with in-depth
expertise across multiple therapeutic areas in quality assurance, regulatory
affairs, business development, and marketing and sales. Food and Drug Administration (FDA) has
granted a Priority Review designation to its Supplemental New Drug Application
(sNDA ) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory
multiple myeloma. The Company is seeking approval to market REVLIMID in combination with
dexamethasone as a proposed indication for the treatment of multiple myeloma
patients who have received at least one prior therapy subject to FDA review
and approval. Myelodysplastic syndromes
occur when blood cells remain in an immature or "blast" stage within the bone
marrow and never develop into mature cells capable of performing their
necessary functions.

pulmonale conjunctivitis

At Glaxo, she created and led a
department of 42 scientific and administrative staff in regulatory affairs and
clinical and manufacturing compliance that led to new product approvals in a
broad range of therapeutic areas.

pulmonale cubital

Jeff also served as President of Hospital Pharmaceuticals
at Faulding Canada Inc. The Company's lead product candidate,
rifalazil, is in Phase 2 clinical trials for multiple indications.
Other adverse events: Other most frequently reported adverse events were
diarrhea, pruritis, rash, fatigue, constipation, nausea, nasopharyngitis,
arthralgia , pyrexia, back pain, peripheral edema, cough, dizziness, headache,
muscle cramp, dyspnea, and pharyngitis . REVLIMID(R) (lenalidomide) is
substantially excreted by the kidney, so the risk of toxic reactions may be
greater in patients with impaired renal function.com.

cryptosporidiosis tapeworms

Director Regulatory Affairs, and Compliance. Based on a pre-specified interim analysis, both
studies achieved the primary endpoint of time to disease progression (TTP)
with combination therapy of lenalidomide and dexamethasone over that of
placebo and dexamethasone.

IMPORTANT SAFETY INFORMATION
Hypersensitivity: REVLIMID(R) (lenalidomide) is contraindicated in any
patients who have demonstrated hypersensitivity to the drug or its components.REVLIMID. A deletion
involving the 5q chromosome may be involved in 20 percent to 30 percent of all
MDS patients.

pulmonale cleidocranial

Expanding clinical pipeline leads to establishment of Canadian Operations

LEXINGTON, Mass. pylori), a bacterium infecting approximately two -
thirds of the world's population.

FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma

The IMiD pipeline, including REVLIMID,
is covered by a comprehensive intellectual property estate of U. However, most
patients with multiple myeloma have cells that produce a form of
immuno-globulin called paraprotein (or M protein) that does not benefit the
body.

cystinosis campylobacteriosis

causalgia abscess

Suzanne Cadden was appointed as Vice President, Regulatory Affairs and
Canadian Operations.
In connection with the formation of Canadian operations, the Company
announced the appointment of Jeff Courtney, General Partner, VenGrowth Private
Equity Partners Inc, to the ActivBiotics Board of Directors. In the year 2005, there were
approximately 200,000 people worldwide suffering from multiple myeloma.

pseudomembranous synthase

, with participation from the Canadian Medical
Discoveries Fund (CMDF) (which is advised by MDS Capital), co-led the
investment to form ActivBiotics (Canada) Inc . THALIDOMIDE IS A KNOWN HUMAN
TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS .

About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharmaceutical company engaged primarily in the discovery, development
and commercialization of innovative therapies for the treatment of cancer and
inflammatory diseases through gene and protein regulation.

This release contains forward-looking statements which are subject to
known and unknown risks, delays, uncertainties and other factors not under the
Company's control, which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance or
other expectations expressed or implied by these forward-looking statements .

cestodes corticobasal

and will also handle operations of
recently established ActivBiotics (Canada), Inc.

HEMATOLOGICAL TOXICITY
(NEUTROPENIA AND THROMBOCYTOPENIA)
REVLIMID(R) (lenalidomide) IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND
THROMBOCYTOPENIA. REVLIMID is
not approved by the FDA or any other regulatory agencies as a treatment for
any other indication and is currently being evaluated in clinical trials for
efficacy and safety for future regulatory applications.celgene.

cerebellar chromosomal

, President and
Chief Executive of ActivBiotics, Inc."
Ms.S.

Special Prescribing Requirements
BECAUSE OF THIS POTENTIAL TOXICITY AND TO AVOID FETAL EXPOSURE TO
REVLIMID(R ) (lenalidomide), REVLIMID(R) (lenalidomide) IS ONLY AVAILABLE UNDER
A SPECIAL RESTRICTED DISTRIBUTION PROGRAM.

REVLIMID(R) is a registered trademark of Celgene Corporation.

clostridial cerebellar

, March 3 - Celgene Corporation
(Nasdaq: CELG) announced that the U. PATIENTS SHOULD HAVE THEIR CBC CHECKED WEEKLY FOR THE FIRST
8 WEEKS OF REVLIMID(R) (lenalidomide) TREATMENT AND AT LEAST MONTHLY
THEREAFTER TO MONITOR FOR CYTOPENIAS.

3. DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
REVLIMID(R) (lenalidomide ) HAS DEMONSTRATED SIGNIFICANT RISK OF DEEP VEIN
THROMBOSIS AND PULMONARY EMBOLISM IN SOME PATIENTS WITH CERTAIN MEDICAL
CONDITIONS. The cause of the disease remains unknown.

About Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a group of hematologic malignancies
that affect approximately 300,000 people worldwide.

synthase ophthalmoplegia

ActivBiotics Inc. Establishes Canadian Operations Appoints Suzanne Cadden to Senior Management Team and Jeff Courtney to the Board of Directors

Mr.com OR BY CALLING THE
MANUFACTURER'S TOLL FREE NUMBER 1-888-4CELGENE. RevAssist(SM) is a proprietary
risk -management restrictive distribution program, tailored specifically for
REVLIMID patients, to prevent the potential for human birth defects and ensure
prompt and convenient access to REVLIMID.

vermis campylobacteriosis

The Prescription Drug User Fee Act (PDUFA) date is June 30,
2006. The
estimated number of deaths from multiple myeloma expected in 2006 is
approximately 60,000 worldwide.

pulmonale corticobasal

D. She held senior positions at CIBA
Canada including acting VP Research + Development and, at Glaxo-Wellcome, Sr. "Rifalazil's unique potency against bacterial infections gives it the
potential to have a major impact in several areas of the multi-billion dollar
infectious disease market. IF
LENALIDOMIDE IS TAKEN DURING PREGNANCY , IT MAY CAUSE BIRTH DEFECTS OR DEATH TO
AN UNBORN BABY. Celgene continues to evaluate REVLIMID in a broad range
of hematology and oncology conditions. For more
information, please visit the Company 's website at http://www.
RevAssist(SM) is a service mark of Celgene Corporation.

ophthalmoplegia chromosomal

The
Company 's lead pre-clinical compound in a pipeline of novel rifamycins, ABI-
0043, shows significant potential for the treatment of infections caused by
Gram-positive pathogens, including Staphylococcus aureus and MRSA
(methicillin-resistant Staphylococcus aureus). Priority Review is granted to a pharmaceutical product that, if
approved, would be a significant improvement compared to existing marketed
products or approved therapies in the treatment, diagnosis, or prevention of a
disease.
The Celgene Expanded Access Program, available to qualified patients with
relapsed or refractory multiple myeloma , will remain open to ensure broad
access to REVLIMID while the REVLIMID sNDA is under review by the FDA. MDS patients must often
rely on blood transfusions to manage symptoms of anemia and fatigue and may
develop life-threatening iron overload and/or toxicity from frequent
transfusions, thus underscoring the critical need for new therapies targeting
the cause of the condition rather than simply managing its symptoms.
These factors include results of current or pending research and development
activities, actions by the FDA and other regulatory authorities, and other
factors described in the Company's filings with the Securities and Exchange
Commission such as our 10K, 10Q and 8K reports .